NasdaqGS:UTHRBiotechs
How Investors Are Reacting To United Therapeutics (UTHR) Q3 Growth, 2027 Outlook and Insider Selling
In late November 2025, United Therapeutics reported a 7% year-over-year revenue increase in its third-quarter fiscal 2025 results, alongside advancing clinical trials and guidance for up to US$4.00 billion in revenue by 2027, while also seeing heightened institutional demand and bullish investor inflows.
Around the same time, company officer Martine A. Rothblatt sold 8,000 shares for about US$3.89 million, adding an insider activity lens to an otherwise growth-focused story.
We’ll now...